Autolus Therapeutics (AUTL) Income towards Parent Company (2017 - 2025)
Historic Income towards Parent Company for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to -$79.1 million.
- Autolus Therapeutics' Income towards Parent Company rose 362.51% to -$79.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.8 million, marking a year-over-year increase of 1680.99%. This contributed to the annual value of -$220.7 million for FY2024, which is 589.25% down from last year.
- Per Autolus Therapeutics' latest filing, its Income towards Parent Company stood at -$79.1 million for Q3 2025, which was up 362.51% from -$47.9 million recorded in Q2 2025.
- In the past 5 years, Autolus Therapeutics' Income towards Parent Company ranged from a high of -$6.8 million in Q4 2021 and a low of -$44.8 billion during Q3 2021
- In the last 5 years, Autolus Therapeutics' Income towards Parent Company had a median value of -$45.8 million in 2023 and averaged -$2.4 billion.
- Per our database at Business Quant, Autolus Therapeutics' Income towards Parent Company tumbled by 8428307.1% in 2021 and then soared by 9990.45% in 2022.
- Autolus Therapeutics' Income towards Parent Company (Quarter) stood at -$6.8 million in 2021, then tumbled by 298.16% to -$27.0 million in 2022, then crashed by 186.04% to -$77.2 million in 2023, then soared by 64.23% to -$27.6 million in 2024, then crashed by 186.6% to -$79.1 million in 2025.
- Its Income towards Parent Company stands at -$79.1 million for Q3 2025, versus -$47.9 million for Q2 2025 and -$70.2 million for Q1 2025.